Table 4 Separate comparisons of the developed sandwich ELISA-like assay using nanobody-HRP fusion as the detection antibody and direct immunofluorescent assay using nanobody-EGFP fusion with real-time PCR and with a commercial monoclonal antibody-based sandwich ELISA by detecting PPV from the clinical samples
Assay | Number | Real-time PCR | Agreement (%) | Kappa value | Commercial monoclonal antibody-based sandwich ELISA | Agreement (%) | Kappa value | |||
|---|---|---|---|---|---|---|---|---|---|---|
+ | − | + | − | |||||||
Developed sandwich ELISA-like assay | + | 23 | 23 | 0 | 92.1 | 0.838 | 14 | 9 | 81.5 | 0.6 |
− | 41 | 5 | 36 | 2 | 39 | |||||
Direct immunofluorescent assay | + | 17 | 17 | 0 | 81.5 | 0.635 | 14 | 3 | 90.8 | 0.796 |
− | 47 | 11 | 36 | 2 | 45 | |||||